A

Allogene Therapeutics
D

ALLO

1.29500
USD
0.01
(0.39%)
قبل الجلسة·1.29000USD-0.00500(-0.39%)
حجم التداول
279,370
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
447,410,691

العنوان: Allogene Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).